Table 1 Used antiviral treatment
From: Therapy of chronic hepatitis C in people who inject drugs: focus on adherence
PWID group (N = 101) | Control group (N = 177) | p | |
|---|---|---|---|
Previous IFN-α treatment | 19 (18.8%) | 69 (39%) | 0.03 |
Direct-acting antivirals combination | |||
Paritaprevir/ritonavir + ombitasvir + dasabuvir 8 or 12 weeks (75/50/12.5/250 mg, three pills in the morning, one pill in the evening) | 41 (40.6%) | 83 (48.7%) | < 0.01 |
Sofosbuvir + ledipasvir 8 or 12 weeks (400/90 mg, one pill once daily) | 18 (17.8%) | 19 (10.7%) | |
Grazoprevir + elbasvir 12 weeks (100/50 mg, one pill once daily) | 19 (18.8%) | 57 (32.2%) | |
Sofosbuvir + velpatasvir 12 weeks (400/100 mg, one pill once daily) | 18 (17.8%) | 10 (5.6%) | |
Sofosbuvir + velpatasvir + voxilaprevir 8 or 12 weeks (400/100/100 mg, one pill once daily) | 3 (3.0%) | 4 (1.4%) | |
Other | 2 (2.0%) | 4 (1.4%) | |
Treatment duration | |||
8 weeks | 27 (26.7%) | 36 (20.3%) | N. S. |
12 weeks | 74 (73.3%) | 141 (79.7%) | |
Use of ribavirin (twice daily according to body weight, 800–1200 mg) | 19 (18.8%) | 22 (12.4%) | N. S. |